Pharmaceutical Sales Certification (PSC) & CNPR
Exam Practice Questions Complete Study Guide with
Verified Answers & Detailed Rationales
2026/2027 Edition | National Association of Pharmaceutical Sales
Representatives (NAPSRx)
1. A pharmaceutical sales representative is preparing a sales call on a large group
practice. The representative has obtained data showing that the practice
prescribes a competitor's drug in 70% of cases for a specific indication. The
representative's drug has a more favorable side effect profile. Which approach is
most appropriate for the opening of the sales call?
• A) "Your practice is prescribing our competitor's drug 70% of the time. Our drug
has fewer side effects."
• B) "I notice you are prescribing the competitor's drug frequently. Can you tell me
about your experience with it?"
• C) "Our drug is superior to the competitor's drug because it has fewer side
effects."
• D) "I understand you are managing many patients with this condition. Our
drug has a favorable side effect profile that may benefit your patients."
Rationale: The most effective opening focuses on the physician's patients and needs, not
on criticizing competitors. Option D is patient-centered and introduces the benefit without
being confrontational. Option B is acceptable but may be perceived as challenging. Option
A and C are too aggressive and may violate fair balance principles by making
unsupported comparative claims.
,2. A sales representative is detailing a new injectable biologic for rheumatoid
arthritis. The physician asks about the drug's pregnancy category. The
representative knows the drug is categorized as Pregnancy Category B. Which of
the following statements accurately conveys the meaning of this categorization?
• A) Studies in pregnant women have shown no risk to the fetus.
• B) Animal studies have not demonstrated a risk to the fetus, but there are no
adequate and well-controlled studies in pregnant women.
• C) There is positive evidence of fetal risk based on human studies.
• D) The drug is contraindicated in pregnancy.
Rationale: Pregnancy Category B indicates that animal reproduction studies have failed to
demonstrate a risk to the fetus, but there are no adequate and well-controlled studies in
pregnant women. Option A describes Category A. Option C describes Category D or X.
Option D describes Category X.
3. A representative is preparing a market analysis for a new oral anticoagulant. The
drug is expected to be priced at a premium compared to warfarin but offers
advantages in dosing convenience and fewer dietary restrictions. Which
stakeholder would be most concerned about the budget impact of this new drug?
• A) The prescribing physician
• B) The patient
• C) The hospital pharmacy director
• D) The Pharmacy and Therapeutics (P&T) Committee and the hospital CFO
Rationale: The P&T Committee evaluates the clinical efficacy, safety, and cost-
effectiveness of new drugs. The CFO is concerned with the budget impact. While physicians
and patients care about cost, the P&T Committee and finance department make
formulary decisions based on overall budget impact. Hospital pharmacy directors also
influence these decisions.
4. A pharmaceutical sales representative is reviewing the FDA's requirements for
direct-to-consumer (DTC) advertising. Which of the following statements is true
regarding DTC advertising regulations?
, • A) DTC ads only need to mention the drug's name and indication, not side
effects.
• B) DTC ads must present a fair balance of benefits and risks, including major
side effects.
• C) DTC ads are not regulated by the FDA.
• D) DTC ads can make unsubstantiated claims if they are in bold print.
Rationale: The FDA requires that DTC advertising present a fair balance of benefits and
risks. This includes disclosing major side effects and contraindications. Option A is
incorrect because side effects must be included. Option C is false; DTC ads are regulated
by the FDA. Option D is false; unsubstantiated claims are prohibited.
5. A pharmaceutical representative is detailing a new drug for hypertension. The
drug's mechanism of action is as an angiotensin receptor blocker (ARB). Which of
the following statements accurately describes how this drug class works?
• A) It blocks the conversion of angiotensin I to angiotensin II
• B) It blocks the binding of angiotensin II to its receptors on blood vessels
• C) It inhibits the renin enzyme
• D) It blocks calcium channels
Rationale: ARBs (e.g., losartan, valsartan) block the binding of angiotensin II to its
receptors on blood vessels, preventing vasoconstriction. ACE inhibitors block the
conversion of angiotensin I to angiotensin II (Option A). Renin inhibitors block renin
(Option C). Calcium channel blockers block calcium channels (Option D).
6. A representative is calling on a physician who is a high prescriber of a
competitor's drug. The physician states, "I've been using the competitor's drug for
years and my patients do well on it." Which response is most appropriate for the
representative?
• A) "Our drug has been proven to be more effective in head-to-head trials."
• B) "I'm surprised you haven't switched to our drug yet."
• C) "The competitor's drug has serious side effects that you may not be aware of."
, • D) "I'm glad your patients are doing well. Our drug offers a different
mechanism that may benefit patients who don't respond adequately to your
current therapy."
Rationale: Option D acknowledges the physician's positive experience while presenting the
new drug as an alternative for specific patient populations. Option A makes an
unsupported claim. Option B is confrontational and unprofessional. Option C may violate
fair balance by exaggerating risks of the competitor's drug.
7. A sales representative is preparing a presentation for a hospital's P&T
Committee. The representative wants to emphasize the drug's cost-effectiveness.
Which metric is most relevant for this audience?
• A) Relative risk reduction
• B) Number needed to treat (NNT)
• C) Absolute risk reduction
• D) Cost per quality-adjusted life year (QALY)
Rationale: Cost per QALY is a standard metric used in pharmacoeconomics to assess cost-
effectiveness. It combines both quality and quantity of life gained. While NNT and risk
reductions are clinically relevant, the P&T Committee is also interested in economic value.
Cost per QALY directly addresses budget impact and value for money.
8. A pharmaceutical sales representative is discussing a new antidepressant with a
psychiatrist. The psychiatrist asks about the drug's effect on weight. The
representative knows the drug is associated with weight gain in some patients.
Which response is most appropriate?
• A) "Weight gain is not a significant issue with this drug."
• B) "The drug may cause weight loss in some patients."
• C) "Weight gain has been reported in clinical trials, but the incidence is
relatively low. We should monitor patients for this side effect."
• D) "I don't have that information available."
Rationale: Option C provides accurate information about the side effect while maintaining
fair balance. Option A is untrue and could mislead the physician. Option B is inaccurate.
Exam Practice Questions Complete Study Guide with
Verified Answers & Detailed Rationales
2026/2027 Edition | National Association of Pharmaceutical Sales
Representatives (NAPSRx)
1. A pharmaceutical sales representative is preparing a sales call on a large group
practice. The representative has obtained data showing that the practice
prescribes a competitor's drug in 70% of cases for a specific indication. The
representative's drug has a more favorable side effect profile. Which approach is
most appropriate for the opening of the sales call?
• A) "Your practice is prescribing our competitor's drug 70% of the time. Our drug
has fewer side effects."
• B) "I notice you are prescribing the competitor's drug frequently. Can you tell me
about your experience with it?"
• C) "Our drug is superior to the competitor's drug because it has fewer side
effects."
• D) "I understand you are managing many patients with this condition. Our
drug has a favorable side effect profile that may benefit your patients."
Rationale: The most effective opening focuses on the physician's patients and needs, not
on criticizing competitors. Option D is patient-centered and introduces the benefit without
being confrontational. Option B is acceptable but may be perceived as challenging. Option
A and C are too aggressive and may violate fair balance principles by making
unsupported comparative claims.
,2. A sales representative is detailing a new injectable biologic for rheumatoid
arthritis. The physician asks about the drug's pregnancy category. The
representative knows the drug is categorized as Pregnancy Category B. Which of
the following statements accurately conveys the meaning of this categorization?
• A) Studies in pregnant women have shown no risk to the fetus.
• B) Animal studies have not demonstrated a risk to the fetus, but there are no
adequate and well-controlled studies in pregnant women.
• C) There is positive evidence of fetal risk based on human studies.
• D) The drug is contraindicated in pregnancy.
Rationale: Pregnancy Category B indicates that animal reproduction studies have failed to
demonstrate a risk to the fetus, but there are no adequate and well-controlled studies in
pregnant women. Option A describes Category A. Option C describes Category D or X.
Option D describes Category X.
3. A representative is preparing a market analysis for a new oral anticoagulant. The
drug is expected to be priced at a premium compared to warfarin but offers
advantages in dosing convenience and fewer dietary restrictions. Which
stakeholder would be most concerned about the budget impact of this new drug?
• A) The prescribing physician
• B) The patient
• C) The hospital pharmacy director
• D) The Pharmacy and Therapeutics (P&T) Committee and the hospital CFO
Rationale: The P&T Committee evaluates the clinical efficacy, safety, and cost-
effectiveness of new drugs. The CFO is concerned with the budget impact. While physicians
and patients care about cost, the P&T Committee and finance department make
formulary decisions based on overall budget impact. Hospital pharmacy directors also
influence these decisions.
4. A pharmaceutical sales representative is reviewing the FDA's requirements for
direct-to-consumer (DTC) advertising. Which of the following statements is true
regarding DTC advertising regulations?
, • A) DTC ads only need to mention the drug's name and indication, not side
effects.
• B) DTC ads must present a fair balance of benefits and risks, including major
side effects.
• C) DTC ads are not regulated by the FDA.
• D) DTC ads can make unsubstantiated claims if they are in bold print.
Rationale: The FDA requires that DTC advertising present a fair balance of benefits and
risks. This includes disclosing major side effects and contraindications. Option A is
incorrect because side effects must be included. Option C is false; DTC ads are regulated
by the FDA. Option D is false; unsubstantiated claims are prohibited.
5. A pharmaceutical representative is detailing a new drug for hypertension. The
drug's mechanism of action is as an angiotensin receptor blocker (ARB). Which of
the following statements accurately describes how this drug class works?
• A) It blocks the conversion of angiotensin I to angiotensin II
• B) It blocks the binding of angiotensin II to its receptors on blood vessels
• C) It inhibits the renin enzyme
• D) It blocks calcium channels
Rationale: ARBs (e.g., losartan, valsartan) block the binding of angiotensin II to its
receptors on blood vessels, preventing vasoconstriction. ACE inhibitors block the
conversion of angiotensin I to angiotensin II (Option A). Renin inhibitors block renin
(Option C). Calcium channel blockers block calcium channels (Option D).
6. A representative is calling on a physician who is a high prescriber of a
competitor's drug. The physician states, "I've been using the competitor's drug for
years and my patients do well on it." Which response is most appropriate for the
representative?
• A) "Our drug has been proven to be more effective in head-to-head trials."
• B) "I'm surprised you haven't switched to our drug yet."
• C) "The competitor's drug has serious side effects that you may not be aware of."
, • D) "I'm glad your patients are doing well. Our drug offers a different
mechanism that may benefit patients who don't respond adequately to your
current therapy."
Rationale: Option D acknowledges the physician's positive experience while presenting the
new drug as an alternative for specific patient populations. Option A makes an
unsupported claim. Option B is confrontational and unprofessional. Option C may violate
fair balance by exaggerating risks of the competitor's drug.
7. A sales representative is preparing a presentation for a hospital's P&T
Committee. The representative wants to emphasize the drug's cost-effectiveness.
Which metric is most relevant for this audience?
• A) Relative risk reduction
• B) Number needed to treat (NNT)
• C) Absolute risk reduction
• D) Cost per quality-adjusted life year (QALY)
Rationale: Cost per QALY is a standard metric used in pharmacoeconomics to assess cost-
effectiveness. It combines both quality and quantity of life gained. While NNT and risk
reductions are clinically relevant, the P&T Committee is also interested in economic value.
Cost per QALY directly addresses budget impact and value for money.
8. A pharmaceutical sales representative is discussing a new antidepressant with a
psychiatrist. The psychiatrist asks about the drug's effect on weight. The
representative knows the drug is associated with weight gain in some patients.
Which response is most appropriate?
• A) "Weight gain is not a significant issue with this drug."
• B) "The drug may cause weight loss in some patients."
• C) "Weight gain has been reported in clinical trials, but the incidence is
relatively low. We should monitor patients for this side effect."
• D) "I don't have that information available."
Rationale: Option C provides accurate information about the side effect while maintaining
fair balance. Option A is untrue and could mislead the physician. Option B is inaccurate.
